Presenting author

Daniel Bonner

1 presentation

• PS02-2029. GlyphAgo demonstrated 6.8-fold bioavailability and 10-fold reduced variability versus unmodified agomelatine at doses projected to mitigate liver exposure in humans

  2026 ECNP Congress